Latest ADHD News
Latest ADHD News From Medical News Today.
Updated: 2 hours 46 sec ago
Celebrity Designer And ADHD Spokesperson Ty Pennington Partners With Shire To Announce The Launch Of VYVANSE™ For Adult ADHD Treatment
Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has launched VYVANSE™ (lisdexamfetamine dimesylate) for the treatment of adults with Attention Deficit Hyperactivity Disorder (ADHD). This launch follows the recent FDA approval of VYVANSE to treat ADHD in the adult population. VYVANSE is now available in U.S. pharmacies nationwide in six once-daily dosage strengths.
Protein On 'Speed' Linked To ADHD
A genetic change in the dopamine transporter - one of the brain's dopamine-handling proteins - makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report this week in The Journal of Neuroscience. The altered function of the transporter gene variant, discovered in two brothers with attention deficit hyperactivity disorder (ADHD), supports a role for dopamine signaling in the disease.
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster And Better Symptom Control Than Concerta(R)1 In Early Part Of ADHD Patients' Day
A head-to-head study, published in the June Journal of Child and Adolescent Psychopharmacology, confirms that Focalin(R) XR (dexmethylphenidate HCl) extended-release capsules offer greater improvements in managing symptoms of Attention Deficit/Hyperactivity Disorder compared with Concerta(R) (d,l- methylphenidate HCl) extended-release tablets at two hours post-dose, the primary study endpoint.
News From The Journal Of Neuroscience
1. Dopamine Transporter Efflux in ADHD Michelle S. Mazei-Robison, Erica Bowton, Marion Holy, Martin Schmudermaier, Michael Freissmuth, Harald H. Sitte, Aurelio Galli, and Randy D. Blakely Elevated dopamine efflux through the dopamine transporter may underlie some forms of attention-deficit hyperactivity disorder (ADHD), according to Mazei-Robison et al.
Innovative Program Focuses On Improved Care For Children With ADHD
An innovative program is helping busy primary care physicians improve the care they provide for school-aged children with Attention-Deficit/Hyperactivity Disorder (ADHD), according to a study led by researchers at Cincinnati Children's Hospital Medical Center and published in the July edition of Pediatrics.
Ritalin-style Drug Set For Wider Role In Adult Mental Illness
A significant number of adults with unresolved depression, anxiety or addiction may actually have Attention Deficit Hyperactivity Disorder (ADHD), a condition that has been widely considered to resolve in late adolescence.
CONCERTA® Now Available For Patients With ADHD Ages 6 To 65 In USA
ADHD is the most common emotional, cognitive and behavioral disorder treated in children1, and according to the National Institute of Mental Health (NIMH), between 30 percent and 70 percent of children with ADHD continue to exhibit symptoms in the adult years 2.
NIMH Funds Pitt Researchers To Find Best Treatments For Children With Autism And ADHD Symptoms
Researchers at the University of Pittsburgh and the Western Psychiatric Institute and Clinic of UPMC have received $3 million from the National Institute of Mental Health to conduct a national study of the treatment of attention deficit hyperactivity disorder (ADHD) in children with autism spectrum disorders.
How Ritalin Works In Brain To Boost Cognition, Focus Attention
Stimulant medications such as Ritalin have been prescribed for decades to treat attention deficit hyperactivity disorder (ADHD), and their popularity as "cognition enhancers" has recently surged among the healthy, as well.What's now starting to catch up is knowledge of what these drugs actually do in the brain.
Concept Media Releases AD/HD, Autism, And Mental Retardation Programs
Concept Media, a leading producer and distributor of healthcare education media, has just released ADHD: Attention Deficit/Hyperactivity Disorder, Autism Spectrum Disorders, and Mental Retardation in DVD and CD-ROM formats. These new scenario-based series have a multidisciplinary focus that features medicine, nursing, education, and human development.
The Gene For ADHD May Have Benefited Our Nomadic Ancestors
An ADHD-associated version of the human gene DRD4 is linked to better health among nomadic tribesmen, but may cause malnourishment in their settled cousins, according to new research by a team directed by an anthropologist at the University of Wisconsin-Milwaukee (UWM).
Sciele Pharma Announces That Addrenex Has Completed Enrollment Of Pivotal Phase III Trial For Clonicel For ADHD
Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, announced that Addrenex Pharmaceuticals has completed patient enrollment of its first Phase III clinical trial in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder (ADHD) in children. Addrenex is also continuing to enroll patients in an additional Phase III trial using Clonicel in combination with stimulants such as methylphenidate and dextro-amphetamine/amphetamine to treat ADHD.
PsychoGenics Announces Positive Phase-IIa For Its First-in-Class Partial 5-HT1A - 5-HT1B Receptor Agonist In ADHD
PsychoGenics Inc. announced positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company's lead partial 5-HT1A - 5-HT1B receptor agonist, in adult patients with Attention Deficit/ Hyperactivity Disorder (ADHD).
Children's Diet Not The Main Cause Of ADHD
Food may not be the major cause of hyperactivity in children. Genetics, brain function and parental actions such as smoking may be just as important.A review of scientific evidence found only a minority of children were actually affected by what they eat. A combination of food, genetics and environmental toxins are more likely to be involved, with no single factor to blame.Foods which might affect behaviour, in particular table sugar were studied.
AAP And American Heart Association Clarify Statement On ADHD And Electrocardiograms
The American Heart Association released on April 21, 2008, a statement about cardiovascular evaluation and monitoring of children receiving drugs for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). As a result of language in the news release and the statement as published, there have been conflicting interpretations of the recommendations regarding the use of an electrocardiogram (ECG) in assessing children with ADHD who may need treatment with medications.
New European Study Showed OROS(R) Methylphenidate Tablets Significantly Improved Symptoms In Adults With ADHD
Adults with attention deficit hyperactivity disorder (ADHD) treated in an investigational study with OROS® methylphenidate tablets experienced significantly greater improvements in their ADHD symptoms compared to patients taking placebo, according to findings from a trial published in Biological Psychiatry.
New European Study Showed OROS(R) Methylphenidate Tablets Significantly Improved Symptoms In Adults With ADHD
Adults with attention deficit hyperactivity disorder (ADHD) treated in an investigational study with OROS® methylphenidate tablets experienced significantly greater improvements in their ADHD symptoms compared to patients taking placebo, according to findings from a trial published in Biological Psychiatry.
FDA Approves Strattera(R) For Maintenance Of ADHD In Children And Adolescents
Eli Lilly and Company (NYSE: LLY) announced that the United States Food and Drug Administration (FDA) has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.
VYVANSE Demonstrated Significant Improvement In ADHD Symptoms In Adults
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints. "Adults with ADHD often find it challenging to focus and organize during the day.
Shire Investigational Nonstimulant INTUNIV Showed Significant Efficacy In Reducing ADHD Symptoms
Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
